Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.44 |
| ▸ | GAA | P10253 | 2/20 | 0.44 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.44 |
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
| ▸ | ADRA2A | P08913 | 2/20 | 0.43 |
| ▸ | ADRA2C | P18825 | 2/20 | 0.43 |
| ▸ | ADRA1D | P25100 | 2/20 | 0.43 |
| ▸ | ADRA1A | P35348 | 2/20 | 0.43 |
| ▸ | ADRA1B | P35368 | 2/20 | 0.43 |
| ▸ | MAP3K14 | Q99558 | 1/20 | 0.43 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.43 |
| ▸ | ITGB2 | P05107 | 1/20 | 0.38 |
| ▸ | ICAM1 | P05362 | 1/20 | 0.38 |
| ▸ | ITGAL | P20701 | 1/20 | 0.38 |
| ▸ | HTR2C | P28335 | 1/20 | 0.37 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
| ▸ | GLA | P06280 | 1/20 | 0.36 |
| ▸ | HPGD | P15428 | 1/20 | 0.36 |
| ▸ | CASP1 | P29466 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3001705 | 0.89 | MAP3K14 (0.41) | ALDH1A1GAAHSD17B10MAPTADRA2A | |
| SCHEMBL8593460 | 0.80 | MAP3K14 (0.38) | ALDH1A1MAP3K14ITGB2ICAM1ITGAL | |
| SCHEMBL23532996 | 0.78 | KDM4E (0.38) | ALDH1A1GAAHSD17B10MAPTADRA2A | |
| SCHEMBL30641376 | 0.77 | ADRA2A (0.40) | ALDH1A1GAAHSD17B10MAPTADRA2A | |
| SCHEMBL20756201 | 0.77 | ADRA2A (0.40) | ALDH1A1GAAHSD17B10MAPTADRA2A | |
| SCHEMBL15202099 | 0.77 | FABP6 (0.40) | ALDH1A1GAAHSD17B10MAPTADRA2A | |
| SCHEMBL5248739 | 0.77 | ITGB2 (0.38) | ALDH1A1GAAHSD17B10MAPTADRA2A | |
| SCHEMBL16404623 | 0.77 | MAPT (0.43) | ALDH1A1GAAHSD17B10MAPTADRA2A | |
| SCHEMBL30343091 | 0.77 | ITGB2 (0.38) | ALDH1A1GAAHSD17B10MAPTADRA2A | |
| SCHEMBL979462 | 0.77 | ITGB2 (0.38) | ALDH1A1GAAHSD17B10MAPTADRA2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 71 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-120091815-A | T-type voltage-gated calcium channel enhancer | 广泛研究所股份有限公司 | 2025-06-03 | — | — | CN | disclosed |
| WO-2024108155-A2 | COMPOUNDS, COMPOSITIONS, AND METHODS | DENALI THERAPEUTICS INC. (US) | 2024-05-23 | — | — | WO | disclosed |
| US-11566022-B2 | 3-(5-methoxy-1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives and uses thereof | NOVARTIS AG (CH) | 2023-01-31 | — | — | US | disclosed |
| US-20230028644-A1 | Low Greenhouse Gas Fuel Compositions | BP OIL INTERNATIONAL LIMITED (GB) | 2023-01-26 | — | — | US | disclosed |
| US-11384057-B2 | Methods for preparing fuel additives | BP OIL INTERNATIONAL LIMITED (GB) | 2022-07-12 | — | — | US | disclosed |
| EP-3414305-B1 | FUEL COMPOSITIONS | BP OIL INT (GB) | 2022-06-15 | — | — | EP | disclosed |
| US-11359151-B2 | Methods for preparing fuel additives | BP OIL INTERNATIONAL LIMITED (GB) | 2022-06-14 | — | — | US | disclosed |
| US-11339343-B2 | Methods for blending fuels | BP OIL INTERNATIONAL LIMITED (GB) | 2022-05-24 | — | — | US | disclosed |
| US-11332682-B2 | Methods for reducing oxidation | BP OIL INTERNATIONAL LIMITED (GB) | 2022-05-17 | — | — | US | disclosed |
| EP-3414303-B1 | USES OF ADDITIVES FOR DEMULSIFYING | BP OIL INT (GB) | 2022-01-26 | — | — | EP | disclosed |
| US-20100093689-A1 | HETEROARYL COMPOUNDS AS P2Y1 RECEPTOR INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY | 2010-04-15 | — | — | US | disclosed |
| EP-2172453-A1 | COMPOUND HAVING 11 ß-HSD1 INHIBITORY ACTIVITY | Taisho Pharmaceutical Co. Ltd. (JP) | 2010-04-07 | — | — | EP | disclosed |
| EP-1751113-B1 | UREA ANTAGONISTS OF P2Y1 RECEPTOR USEFUL IN THE TREATMENT OF THROMBOTIC CONDITIONS | BRISTOL MYERS SQUIBB CO (US) | 2010-03-10 | — | — | EP | disclosed |
| US-7645778-B2 | Heteroaryl compounds as P2Y1 receptor inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2010-01-12 | — | — | US | disclosed |
| US-20090318436-A1 | Fused heterocyclic derivatives and methods of use | AMGEN INC. (US) | 2009-12-24 | — | — | US | disclosed |
| US-20080305169-A1 | Pharmaceutical Compositions Comprising Nitrogen-Containing Fused Ring Coumpounds | JAPAN TOBACCO INC. (JP) | 2008-12-11 | — | — | US | disclosed |
| US-7388021-B2 | Urea antagonists of P2Y1 receptor useful in the treatment of thrombotic conditions | BRISTOL MYERS SQUIBB COMPANY (US) | 2008-06-17 | — | — | US | disclosed |
| US-20080064871-A1 | Production Method of Nitrogen-Containing Fused Ring Compounds | JAPAN TOBACCO INC. (JP) | 2008-03-13 | — | — | US | disclosed |
| EP-1820515-A1 | NITROGEN-CONTAINING FUSED RING COMPOUND AND USE THEREOF | Japan Tobacco, Inc. (JP) | 2007-08-22 | — | — | EP | disclosed |
| US-20070010670-A1 | Nitrogen-containing fused ring compounds and use thereof | JAPAN TOBACCO INC. (JP) | 2007-01-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11384057-B2 | Methods for preparing fuel additives | POLB, IDH2, TOP2B | ALDH1A1 264/4885GAA 1452/4885HSD17B10 676/4885 |
| US-20090318436-A1 | Fused heterocyclic derivatives and methods of use | HGF, HGFAC, MET | ALDH1A1 156/4885GAA 79/4885HSD17B10 876/4885 |
| US-20100093689-A1 | HETEROARYL COMPOUNDS AS P2Y1 RECEPTOR INHIBITORS | P2RY1, P2RY11, P2RY2 | ALDH1A1 2158/4885GAA 2336/4885HSD17B10 3848/4885 |
| US-11566022-B2 | 3-(5-methoxy-1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives and uses thereof | HBZ, ZFX, HBG1 | ALDH1A1 715/4885GAA 1087/4885HSD17B10 1799/4885 |
| US-20080305169-A1 | Pharmaceutical Compositions Comprising Nitrogen-Containing Fused Ring Coumpounds | NOD1, NLRP3, SLC10A1 | ALDH1A1 1306/4885GAA 1938/4885HSD17B10 313/4885 |
| US-11359151-B2 | Methods for preparing fuel additives | GSDMD, SCD, FADS1 | ALDH1A1 1572/4885GAA 1486/4885HSD17B10 159/4885 |
| US-20070010670-A1 | Nitrogen-containing fused ring compounds and use thereof | NUDT1, NOD1, SLC28A1 | ALDH1A1 605/4885GAA 3626/4885HSD17B10 633/4885 |
| US-20080064871-A1 | Production Method of Nitrogen-Containing Fused Ring Compounds | NOD1, XDH, URB2 | ALDH1A1 1553/4885GAA 3500/4885HSD17B10 516/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.